Study of CTI-1601 for people with Friedreich's ataxia
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Friedreich's ataxia (FRDA).
- Your blood sugar level (HbA1c) is 7.0% or lower.
- You can give yourself daily injections under the skin, or have a caregiver who can do it for you.
- If you take certain other medicines, you must have been on the same dose for at least 28 days (or 90 days for niacin or resveratrol) before starting the study.
- You do not have serious heart problems or other conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Friedreich's ataxia (FA) over time to learn more about the disease. It helps researchers understand how FA affects people of all ages and may lead to better treatments.
This study looks at how heart disease progresses in people with Friedreich's ataxia, a genetic condition that affects coordination and heart health. By taking part, you help researchers better understand the condition, which may guide future treatments.
This trial tests an investigational drug called DT-216P2 in people with Friedreich's ataxia. It aims to find the right dose and see how safe and tolerable it is.
This study tests a new medicine called DT-216P2 in healthy people to find a safe dose. It is a first step in developing a treatment for Friedreich ataxia, a genetic condition that affects movement and balance.
This study tests an investigational drug given as a daily injection to see if it can improve walking and balance in people with Friedreich's ataxia.
This study tests a new medicine called ATI-105 in healthy adults to see if it is safe and how the body handles it. If you are generally healthy, you might be able to participate and help researchers learn more about this potential treatment.
Hear when a new Friedreich Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.